Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Merger or Acquisition (July 2026)
16 slides from Sanara Medtech's merger presentation, Jul 29, 2026
Slide 1: MIMEDX to Acquire Sanara MedTech
MIMEDX to Acquire Sanara MedTech Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross
Slide 2: Strategic and Financial Benefits of the Transaction
dedication, and I look forward to bringing our teams together to build a stronger business with even greater opportunity in surgical care.” Strategic and Financial Benefits of the Transaction This merger of MIMEDX and Sanara is expected to result in a stronger long-term growth profile with significa
Slide 3: Transaction approvals, conference call and advisors
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Comp
Slide 4: Important Cautionary Statement
Important Cautionary Statement This press release includes forward-looking statements, including statements regarding (i) our expectations for future financial results, including revenue and Adjusted EBITDA margin; (ii) the expected strategic and financial benefits of the proposed combination with S
Slide 5: Additional Information and Where to Find It
In connection with the proposed transaction, MIMEDX intends to file with the SEC a registration statement on Form S-4 that will include a proxy statement of Sanara and that also constitutes a prospectus of MIMEDX. Each of MIMEDX and Sanara may also file other relevant documents with the SEC regardin
Slide 6: Investor Relations Contact
Walter Frank/John Nesbett IMS Investor Relations wfrank@imsinvestorrelations.com
Slide 7: MIMEDX to Acquire Sanara MedTech July 29, 2026
MIMEDX to Acquire Sanara MedTech July 29, 2026
Slide 8: Disclaimer: Forward-Looking Statements
Disclaimer FORWARD-LOOKING STATEMENTS Please note that in this presentation the Company may discuss events or results that have not yet occurred or been realized, commonly referred to as forward-looking statements. Such discussion and statements may contain words such as “expect,” “anticipate,” “wil
Slide 9: Disclaimer: No Offer or Solicitation
Disclaimer No Offer or Solicitation This presentation does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any securities or a solicitation of any vote or approval with respect to the Transactions or otherwise, nor shall there be any sale, issuance or transfer
Slide 10: Leading Surgical-Focused Combination Driving Growth, Scale & Profitability
Leading Surgical-Focused Combination Driving Growth, Scale & Profitability | 4 | HEAL PROTECT HUMANS PROMOTE HELPING PREPARE
Slide 11: Sanara Meaningfully Accelerates Efforts to Expand Surgical Footprint
Sanara Meaningfully Accelerates Efforts to Expand Surgical Footprint | 5 | 100% Surgical / OR Business Leading Particulate Expanding Product Portfolio Unlocks Sizable Incremental TAMs1 +$4B Transforms Surgical Footprint & Financial Profile Robust R&D Pipeline Key Transaction Highlights 1 – Calculate
Slide 12: About Sanara MedTech
About Sanara MedTech Pure-play surgical solutions business focused on the operating room setting, with innovative technologies, strong IP, a proven and scalable commercial engine and a compelling margin profile. 1 – Historical financial information based on Sanara’s public filings | 6 | PREPARE PROM
Slide 13: Strong Business Alignment Drives Compelling Deal Rationale
CellerateRX® Surgical Leading Collagen Particulate Strong Business Alignment Drives Compelling Deal Rationale | 7 | OsStic Synthetic Injectable Structural Bio-Adhesive BIASURGE® No-Rinse Surgical Irrigation Solution Expands Product Offering with Differentiated, Innovative Technologies Strong Cultura
Slide 14: Combination Provides Scale Via Multiple Surgical Commercial Channels
Combination Provides Scale Via Multiple Surgical Commercial Channels | 8 | Transaction grows surgical footprint across soft tissue and musculoskeletal categories MIMEDX Surgical (Soft Tissue) Sanara Surgical (Soft Tissue) Sanara Surgical (Musculoskeletal) Combined Surgical Revenue Combined 2027 Surg
Slide 15: Transaction Transforms Surgical Footprint & Strengthens Financial Profile
Transaction Transforms Surgical Footprint & Strengthens Financial Profile 1 – Based on Management Estimates 2 – 2026 Financial outlook provided on July 29, 2026; actual results may differ 3 – Based upon revenue mix year-to-date through June 30, 2026 | 9 | Surgical Soft Tissue Surgical Musculoskeleta
Slide 16: Transaction Details
Transaction Details | 10 | Consideration Run-Rate Cost Synergies & Combined Financial Profile Timing / Approvals • Acquiring Sanara for $35 per share, representing a 46% premium to Sanara’s 30-day volume weighted average share price as of July 28, 2026 • Purchase price comprised of: • $33 per share